Truncation of WT1 results in downregulation of cyclin G1 and IGFBP-4 expression.
Mutations in the WT1 gene are found in a subset of Wilms' tumours and in certain other disorders such as Denys-Drash syndrome. The WT1 gene product is a zinc finger transcription factor for which many target genes have been suggested. Here we utilise gene targeting to generate cells containing only truncated forms of WT1, in which the DNA-binding region is disrupted. Examination of gene expression in these cells using cDNA macroarrays suggests two novel WT1 transcriptional targets, cyclin G1 (Ccng1), and insulin-like growth factor binding protein 4 (Igfbp4).
Wagner
K J
KJ
Sir Alastair Currie CRC Laboratories, Molecular Medicine Centre, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, United Kingdom.
Patek
C E
CE
Miles
C
C
Christie
S
S
Brookes
A J
AJ
Hooper
M L
ML
D000970:Antineoplastic Agents / Q000494:pharmacology; D002460:Cell Line; D056746:Cyclin G; D056766:Cyclin G1; D016213:Cyclins / Q000235:genetics* / Q000378:metabolism; D015536:Down-Regulation; D018390:Gene Targeting / Q000379:methods*; D006801:Humans; D018974:Insulin-Like Growth Factor Binding Protein 4 / Q000235:genetics* / Q000378:metabolism; D020411:Oligonucleotide Array Sequence Analysis; D014212:Tretinoin / Q000494:pharmacology; D025721:WT1 Proteins / Q000235:genetics* / Q000378:metabolism
D000970:Antineoplastic Agents; C534702:CCNG1 protein, human; D056746:Cyclin G; D056766:Cyclin G1; D016213:Cyclins; D018974:Insulin-Like Growth Factor Binding Protein 4; D025721:WT1 Proteins; D014212:Tretinoin